thought call
think modest perform like littl eas
concern compani trajectori especi given loom humira
diversif issu inde updat revenu guidanc reflect
growth oper perform reduc larg
basi updat fx although outlook hcv modestli increas
caution potenti step-down patient volum
suggest franchis may overal growth driver initi project
commerci still plenti breath roomcurr guidanc still reflect
impress top-lin y/i growth humira biosimilar set launch
eu question sourc revenu replac like persist
especi compani project sale recent approv
orilissa given work necessari build market posit overal
outlook orilissa forecast sale see abbv/nbix thought
orilissa elagolix approv unclear nearer-term growth
driver like declin overal hcv market increasingli competit dynam
 late stage asset risankizumab upadacitinib see continu
believ share fairli valu absent transform busi deal outsid
recent share tender see littl overal upsid potenti stock maintain
equal weight rate price target
pipelin updat regulatori submiss upadacitinib ra set
risankizumab fda file psoriasi accept april decis expect
applic venclexta aml also submit orilissa low-
dose hormon uterin fibroid trial remain track support submiss
model chang given recent trend adjust revenu forecast
also adjust opex estim adjust
ep within updat guidanc
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concer futur franchis
piplin beyond core product
interest like sucess unsur
enough make revenu come
introduct humira biosimilar
pipelin sucess multipl asset indic
would drive revenu thu share price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimialr
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay abbvi inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
